scispace - formally typeset
A

Antonio Cao

Researcher at University of California, San Francisco

Publications -  64
Citations -  3331

Antonio Cao is an academic researcher from University of California, San Francisco. The author has contributed to research in topics: Thalassemia & Hepatitis. The author has an hindex of 27, co-authored 64 publications receiving 3137 citations. Previous affiliations of Antonio Cao include University of Cagliari.

Papers
More filters
Journal ArticleDOI

Isolation of NF-E2-related factor 2 (Nrf2), a NF-E2-like basic leucine zipper transcriptional activator that binds to the tandem NF-E2/AP1 repeat of the beta-globin locus control region.

TL;DR: Although Nrf2 is expressed ubiquitously, a role of this protein in mediating enhancer activity of hypersensitive site 2 in erythroid cells cannot be excluded and NRF2 contains a powerful acidic activation domain that may participate in the transcriptional stimulation of beta-globin genes.
Journal ArticleDOI

Hepatitis C virus in multiple episodes of acute hepatitis in polytransfused thalassaemic children

TL;DR: HCV infection may not induce protective immunity, which has implications for vaccine development and is investigated in three polytransfused thalassaemic children.
Journal ArticleDOI

Initiation codon mutation as a cause of alpha thalassemia.

TL;DR: Cloning and sequence analysis of the alpha-globin genes from a Sardinian patient with the nondeletion type of hemoglobin-H disease revealed a new type of thalassemia lesion, where six patients had the initiation codon lesion.
Journal ArticleDOI

Effect of iron overload on the response to recombinant interferon-alfa treatment in transfusion-dependent patients with thalassemia major and chronic hepatitis C

TL;DR: It is concluded that IFN-alpha represents a useful therapeutic option for children with transfusion-dependent thalassemia and chronic active hepatitis C with a mild to moderate iron burden.
Journal ArticleDOI

A gene dosage effect of the DQA1*0501/DQB1*0201 allelic combination influences the clinical heterogeneity of celiac disease.

TL;DR: It is suggested that a double dose of DQA1*0501, DQB1*0201 genes may predispose a person to an earlier onset and to more severe disease manifestations.